肝动脉输注化疗与经动脉化疗栓塞治疗不可切除肝癌:一项系统回顾和荟萃分析。

IF 1.6 4区 医学 Q2 Medicine Acta Clinica Belgica Pub Date : 2023-04-01 DOI:10.1080/17843286.2022.2076791
Shun-Yu Kong, Jiao-Jiao Song, Yao-Qi Jin, Man-Jun Deng, Jing-Xin Yan
{"title":"肝动脉输注化疗与经动脉化疗栓塞治疗不可切除肝癌:一项系统回顾和荟萃分析。","authors":"Shun-Yu Kong,&nbsp;Jiao-Jiao Song,&nbsp;Yao-Qi Jin,&nbsp;Man-Jun Deng,&nbsp;Jing-Xin Yan","doi":"10.1080/17843286.2022.2076791","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>We carried out a systematic review and meta-analysis to assess the safety and effectiveness of hepatic arterial infusion chemotherapy (HAIC) compared with transarterial chemoembolization (TACE) for patients with unresectable hepatocellular carcinoma (uHCC).</p><p><strong>Methods: </strong>Eligible studies were searched by MEDLINE, the Cochrane Library, Embase, and Web of Science from January 1995 to January 2022, investigating eligible literature comparing HAIC and TACE for patients with HCC. The main outcome measures included progression-free survival (PFS), overall survival (OS), adverse events (AEs), objective response rate (ORR), and diseases control rate (DCR).</p><p><strong>Results: </strong>Eight literature and 1028 patients were enrolled in this meta-analysis. The pooled PFS, OS, ORR, and DCR were HR = 0.89 (95% CI, 0.81-0.98), HR = 0.84 (95% CI, 0.75-0.93), OR = 2.77 (95% CI, 2.01-3.80), and OR = 4.64 (95% CI, 2.40-8.99), respectively. The adverse events of HAIC were lower than TACE.</p><p><strong>Conclusion: </strong>Our meta-analysis revealed that HAIC can achieve a better effect and survival benefits than TACE in patients with uHCC.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":"78 2","pages":"171-179"},"PeriodicalIF":1.6000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis.\",\"authors\":\"Shun-Yu Kong,&nbsp;Jiao-Jiao Song,&nbsp;Yao-Qi Jin,&nbsp;Man-Jun Deng,&nbsp;Jing-Xin Yan\",\"doi\":\"10.1080/17843286.2022.2076791\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>We carried out a systematic review and meta-analysis to assess the safety and effectiveness of hepatic arterial infusion chemotherapy (HAIC) compared with transarterial chemoembolization (TACE) for patients with unresectable hepatocellular carcinoma (uHCC).</p><p><strong>Methods: </strong>Eligible studies were searched by MEDLINE, the Cochrane Library, Embase, and Web of Science from January 1995 to January 2022, investigating eligible literature comparing HAIC and TACE for patients with HCC. The main outcome measures included progression-free survival (PFS), overall survival (OS), adverse events (AEs), objective response rate (ORR), and diseases control rate (DCR).</p><p><strong>Results: </strong>Eight literature and 1028 patients were enrolled in this meta-analysis. The pooled PFS, OS, ORR, and DCR were HR = 0.89 (95% CI, 0.81-0.98), HR = 0.84 (95% CI, 0.75-0.93), OR = 2.77 (95% CI, 2.01-3.80), and OR = 4.64 (95% CI, 2.40-8.99), respectively. The adverse events of HAIC were lower than TACE.</p><p><strong>Conclusion: </strong>Our meta-analysis revealed that HAIC can achieve a better effect and survival benefits than TACE in patients with uHCC.</p>\",\"PeriodicalId\":7086,\"journal\":{\"name\":\"Acta Clinica Belgica\",\"volume\":\"78 2\",\"pages\":\"171-179\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2023-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Clinica Belgica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/17843286.2022.2076791\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Clinica Belgica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17843286.2022.2076791","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 4

摘要

背景:我们进行了一项系统回顾和荟萃分析,以评估肝动脉输注化疗(HAIC)与经动脉化疗栓塞(TACE)对不可切除肝细胞癌(uHCC)患者的安全性和有效性。方法:从1995年1月至2022年1月,通过MEDLINE、Cochrane图书馆、Embase和Web of Science检索符合条件的研究,调查比较HAIC和TACE治疗HCC患者的符合条件的文献。主要结局指标包括无进展生存期(PFS)、总生存期(OS)、不良事件(ae)、客观缓解率(ORR)和疾病控制率(DCR)。结果:8篇文献和1028例患者纳入本荟萃分析。合并PFS、OS、ORR和DCR分别为HR = 0.89 (95% CI, 0.81-0.98)、HR = 0.84 (95% CI, 0.75-0.93)、OR = 2.77 (95% CI, 2.01-3.80)和OR = 4.64 (95% CI, 2.40-8.99)。HAIC组的不良事件低于TACE组。结论:我们的荟萃分析显示,在uHCC患者中,HAIC比TACE可以获得更好的疗效和生存获益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis.

Background: We carried out a systematic review and meta-analysis to assess the safety and effectiveness of hepatic arterial infusion chemotherapy (HAIC) compared with transarterial chemoembolization (TACE) for patients with unresectable hepatocellular carcinoma (uHCC).

Methods: Eligible studies were searched by MEDLINE, the Cochrane Library, Embase, and Web of Science from January 1995 to January 2022, investigating eligible literature comparing HAIC and TACE for patients with HCC. The main outcome measures included progression-free survival (PFS), overall survival (OS), adverse events (AEs), objective response rate (ORR), and diseases control rate (DCR).

Results: Eight literature and 1028 patients were enrolled in this meta-analysis. The pooled PFS, OS, ORR, and DCR were HR = 0.89 (95% CI, 0.81-0.98), HR = 0.84 (95% CI, 0.75-0.93), OR = 2.77 (95% CI, 2.01-3.80), and OR = 4.64 (95% CI, 2.40-8.99), respectively. The adverse events of HAIC were lower than TACE.

Conclusion: Our meta-analysis revealed that HAIC can achieve a better effect and survival benefits than TACE in patients with uHCC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Acta Clinica Belgica
Acta Clinica Belgica 医学-医学:内科
CiteScore
2.90
自引率
0.00%
发文量
44
审稿时长
6-12 weeks
期刊介绍: Acta Clinica Belgica: International Journal of Clinical and Laboratory Medicine primarily publishes papers on clinical medicine, clinical chemistry, pathology and molecular biology, provided they describe results which contribute to our understanding of clinical problems or describe new methods applicable to clinical investigation. Readership includes physicians, pathologists, pharmacists and physicians working in non-academic and academic hospitals, practicing internal medicine and its subspecialties.
期刊最新文献
Flemish consensus statement on the prevention, diagnosis and treatment of urinary tract infections in older nursing home residents. Validation of EUCAST rapid antimicrobial susceptibility testing directly from positive blood cultures in a non-automated lab setting. A multimodal treatment of basilar artery re-occlusion - case report. 'Iatrogenic septic pit': empyema, a rare complication after endobronchial valve placement. The first reported familial case of statin-induced immune-mediated necrotizing myopathy associated with anti-hydroxy-3-methylglutaryl-CoA reductase autoantibodies and HLA DRB1*11:01
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1